Skip to main content

Disitamab Vedotin: First Approval

Abstract

Disitamab vedotin (Aidixi®) is an antibody–drug conjugate comprising a monoclonal antibody against human epidermal growth factor receptor 2 (HER2) conjugated via a cleavable linker to the cytotoxic agent monomethyl auristatin E. Disitamab vedotin is being developed by RemeGen for the treatment of solid tumours, including gastric cancer; Seagen has the right to develop disitamab vedotin globally outside of RemeGen’s territory. In June 2021, disitamab vedotin received its first Biologics License Application (BLA) approval in China for the treatment of patients with HER2-overexpressing (defined as IHC2+ or 3+) locally advanced or metastatic gastric cancer (including gastroesophageal junction adenocarcinoma) who have received at least two systemic chemotherapy regimens. Disitamab vedotin as monotherapy or combination therapy is also in clinical development for the treatment of other solid tumours globally, including urothelial cancer in China and the USA, and biliary tract cancer, non-small cell lung cancer and HER2-positive and HER2-low expressing breast cancer in China. This article summarizes the milestones in the development of disitamab vedotin leading to this first approval for locally advanced or metastatic gastric cancer.

This is a preview of subscription content, access via your institution.

References

  1. 1.

    ADC Review. What are antibody-drug conjugates (ADCs)? 2019. https://www.adcreview.com/the-review/antibody-drug-conjugates/what-are-antibody-drug-conjugates/. Accessed 16 Jul 2021.

  2. 2.

    RemeGen. Disitamab vedotin: Chinese prescribing information. Yantai 2021.

  3. 3.

    Li L, Xu MZ, Wang L, et al. Conjugating MMAE to a novel anti-HER2 antibody for selective targeted delivery. Eur Rev Med Pharmacol Sci. 2020;24(24):12929–37.

    CAS  PubMed  Google Scholar 

  4. 4.

    RemeGen. Products: product pipeline. 2021. http://www.remegen.com/. Accessed 16 July 2021.

  5. 5.

    National Medical Products Administration. Disitamab vedotin: NMPA Approval notice. 2021. https://www.nmpa.gov.cn/yaowen/ypjgyw/20210609085452194.html. Accessed 9 Sep 2021.

  6. 6.

    Hogan Lovells. The China Food and Drug Administration pushes forward on conditional approval and compassionate use of new drugs. Washington DC 2018.

  7. 7.

    RemeGen. 2020 Annual report. https://www.remegen.com. Accessed 16 Jul 2021.

  8. 8.

    U.S. Food and Drug Administration. Orphan drug designations and approvals. 2021. https://www.accessdata.fda.gov/scripts/opdlisting/oopd/detailedIndex.cfm?cfgridkey=649418. Accessed 16 Jul 2021.

  9. 9.

    RemeGen. RemeGen announces US FDA has granted breakthrough therapy designation for disitamab vedotin (RC48) in urothelial cancer [media release]. 25 Sep 2020. http://www.remegen.com.

  10. 10.

    RemeGen. Disitamab vedotin has been granted breakthrough designations in the United States and China, new drug application (NDA) of urothelial carcinoma was accepted [media release]. 15 Jul 2021. http://www.remegen.com/.

  11. 11.

    Seagen Inc, RemeGen. Seagen and RemeGen announce exclusive worldwide license and co-development agreement for disitamab vedotin [media release]. 9 Aug 2021. https://www.seagen.com/.

  12. 12.

    Yantai Rongchang Pharmaceutical. Rongchang Pharmaceutical received a press attention from the press conference on the 30th anniversary of the development zone [media release]. 17 Oct 2014. http://www.rongchang.com.

  13. 13.

    Yantai Rongchang Biological Engineering Co Ltd. Anti-HER2 antibody and conjugate thereof RC48. 2020. https://patents.google.com/patent/WO2015074528A1/en. Accessed 9 Sep 2021.

  14. 14.

    Peng Z, Liu T, Wei J, et al. A phase II study of efficacy and safety of RC48-ADC in patients with locally advanced or metastatic HER2-overexpressing gastric or gastroesophageal junction cancers [abstract no. 4560]. J Clin Oncol. 2020;38(15 Suppl)

  15. 15.

    Sheng X, He Z, Han W, et al. An open-label, single-arm, multicenter, phase II study of RC48-ADC to evaluate the efficacy and safety of subjects with HER2 overexpressing locally advanced or metastatic urothelial cancer (RC48-C009) [abstract no. 4584]. J Clin Oncol. 2021;39(15 Suppl).

  16. 16.

    Sheng X, Yan X, Wang L, et al. Open-label, multicenter, phase II study of RC48-ADC, a HER2-targeting antibody-drug conjugate, in patients with locally advanced or metastatic urothelial carcinoma. Clin Cancer Res. 2021;27(1):43–51.

    CAS  Article  Google Scholar 

  17. 17.

    Xu H, Sheng X, Yan X, et al. A phase II study of RC48-ADC in HER2-negative patients with locally advanced or metastatic urothelial carcinoma [abstract no. e17113]. J Clin Oncol. 2020;38(15 Suppl).

  18. 18.

    Zhou L, Xu H, Yan X, et al. RC48-ADC combined with toripalimab, an anti-PD-1 monoclonal antibody (Ab), in patients with locally advanced or metastatic urothelial carcinoma (UC): preliminary results of a phase Ib/II study [abstract no. 4534]. J Clin Oncol. 2021;39(15 Suppl).

  19. 19.

    Xu B, Wang J, Fang J, et al. Early clinical development of RC48-ADC in patients with HER2 positive metastatic breast cancer [abstract no. PD4-06]. Cancer Res. 2019;80(4 Suppl).

  20. 20.

    Wang J, Liu Y, Zhang Q, et al. RC48-ADC, a HER2-targeting antibody-drug conjugate, in patients with HER2-positive and HER2-low expressing advanced or metastatic breast cancer: a pooled analysis of two studies [abstract no. 1022]. J Clin Oncol. 2021;39(15 Suppl).

  21. 21.

    Xu Y, Wang Y, Gong J, et al. Phase I study of the recombinant humanized anti-HER2 monoclonal antibody-MMAE conjugate RC48-ADC in patients with HER2-positive advanced solid tumors. Gastric Cancer. 2021;24(4):913–25.

    CAS  Article  Google Scholar 

Download references

Funding

The preparation of this review was not supported by any external funding.

Author information

Affiliations

Authors

Corresponding author

Correspondence to Emma D. Deeks.

Ethics declarations

Conflict of interest

During the peer review process the manufacturer of the agent under review was offered an opportunity to comment on the article. Changes resulting from any comments received were made by the authors on the basis of scientific completeness and accuracy. Emma Deeks is a contracted employee of Adis International Ltd/Springer Nature, and declares no relevant conflicts of interest. All authors contributed to the review and are responsible for the article content.

Ethics approval, Consent to participate, Consent to publish, Availability of data and material, Code availability

Not applicable.

Additional information

This profile has been extracted and modified from the AdisInsight database. AdisInsight tracks drug development worldwide through the entire development process, from discovery, through pre-clinical and clinical studies to market launch and beyond.

Supplementary Information

Below is the link to the electronic supplementary material.

Supplementary file1 (PPTX 506 KB)

Rights and permissions

Reprints and Permissions

About this article

Verify currency and authenticity via CrossMark

Cite this article

Deeks, E.D. Disitamab Vedotin: First Approval. Drugs 81, 1929–1935 (2021). https://doi.org/10.1007/s40265-021-01614-x

Download citation